Companies/Phio Pharmaceuticals Corp.

Company profile

Phio Pharmaceuticals Corp.

NASDAQ: PHIO · Healthcare · Biotechnology

PublicHQ Marlborough, PACIK 0001533040Reports USD

#1143 of 1,394 Healthcare companies by revenuebottom-decile growth

EA Score

40D

FH 53DQ 36GM 5SS 44

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, listing tenure · ↓ revenue growth (YoY), 3-yr revenue growth

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$8.7M

Employees

Market cap

$11.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02020

Net income-$8.7M-$8.7M2025

Operating income-$9.2M-$9.2M2025

Total assets$21.5M$21.5M2025

Liabilities$1.3M$1.3M2025

Equity$20.1M$20.1M2025

Revenue trend

FY2012 – FY2020 · USD

$97.0k

FY12

$399.0k

FY13

$34.0k

FY16

$19.0k

FY16

$15.0k

FY17

$138.0k

FY18

$21.0k

FY19

FY20

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Phio Pharmaceuticals Corp. booked $0 in FY2020 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Kiora Pharmaceuticals, Inc.52D VolitionRX Ltd38D Lexaria Bioscience Corp.43D VYNE Therapeutics Inc.38D

Key facts

CEORobert L. Bitterman

SectorHealthcare

IndustryBiotechnology

HeadquartersMarlborough, PA

ExchangeNASDAQ: PHIO

Employees6

IPO date2012-05-10

Latest filings

8-K2026-05-07 10-Q2026-05-07 8-K2026-04-08 8-K2026-03-30 10-K2026-03-05 8-K2026-03-05 8-K2026-02-18 8-K2026-02-10

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.